Literature DB >> 9511045

Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli.

M Oethinger1, W V Kern, J D Goldman, S B Levy.   

Abstract

Fluoroquinolone resistance in Escherichia coli is principally caused by two kinds of mutation: those affecting the target proteins of the drugs, i.e. DNA gyrase and topoisomerase IV, and those affecting regulatory genes such as marA, soxS or robA. Recently, overexpression of the latter genes was linked to increased organic solvent tolerance in E. coli. Among 138 clinical fluoroquinolone-resistant and -susceptible clinical isolates of E. coli we found a high association between fluoroquinolone resistance and organic solvent tolerance. This finding suggests that E. coli may undergo an adaptive response to extrinsic substances other than quinolones, while mutating to fluoroquinolone resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9511045     DOI: 10.1093/jac/41.1.111

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  The periplasmic protein MppA requires an additional mutated locus to repress marA expression in Escherichia coli.

Authors:  Xiaowen Bina; Vincent Perreten; Stuart B Levy
Journal:  J Bacteriol       Date:  2003-02       Impact factor: 3.490

3.  Characterization of RarA, a novel AraC family multidrug resistance regulator in Klebsiella pneumoniae.

Authors:  Mark Veleba; Paul G Higgins; Gerardo Gonzalez; Harald Seifert; Thamarai Schneiders
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

4.  Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131.

Authors:  James R Johnson; Stephen B Porter; Paul Thuras; Timothy J Johnson; Lance B Price; Veronika Tchesnokova; Evgeni V Sokurenko
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 5.  Extremophiles: from abyssal to terrestrial ecosystems and possibly beyond.

Authors:  Francesco Canganella; Juergen Wiegel
Journal:  Naturwissenschaften       Date:  2011-03-11

Review 6.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

7.  The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Xiangqun Mao; Xiaoyan Han; Neil O Fishman; Warren B Bilker; Pam Tolomeo; Mary Wheeler; Irving Nachamkin
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

8.  Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.

Authors:  H Wang; J L Dzink-Fox; M Chen; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

9.  Escherichia coli mar and acrAB mutants display no tolerance to simple alcohols.

Authors:  Jonas Ankarloo; Susanne Wikman; Ian A Nicholls
Journal:  Int J Mol Sci       Date:  2010-03-31       Impact factor: 5.923

10.  Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.

Authors:  Patricia Komp Lindgren; Asa Karlsson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.